Pycnogenol® 可改善中风后患者的认知功能:一项为期6个月的研究。

IF 1.3 4区 医学 Q4 CLINICAL NEUROLOGY Journal of neurosurgical sciences Pub Date : 2024-02-01 DOI:10.23736/S0390-5616.22.05855-6
Gianni Belcaro, Mark Dugall, Morio Hosoi, Beatrice Feragalli, Roberto Cotellese, Aristide Saggino, Maria Rosaria Cesarone, Edmondo Ippolito, Umberto Cornelli, Andrea Ledda, David B Cox
{"title":"Pycnogenol® 可改善中风后患者的认知功能:一项为期6个月的研究。","authors":"Gianni Belcaro, Mark Dugall, Morio Hosoi, Beatrice Feragalli, Roberto Cotellese, Aristide Saggino, Maria Rosaria Cesarone, Edmondo Ippolito, Umberto Cornelli, Andrea Ledda, David B Cox","doi":"10.23736/S0390-5616.22.05855-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This pilot study in post-stroke patients evaluated the effects of supplementation with Pycnogenol<sup>®</sup> on alterations in cognitive functions (COFU) over a period of 6 months, starting 4 weeks after the stroke.</p><p><strong>Methods: </strong>The effects of supplementation - possibly acting on residual brain edema, on global cognitive function, attention and on mental performance - were studied. A control group used standard management (SM) and the other group added Pycnogenol<sup>®</sup>, 150 mg daily to SM.</p><p><strong>Results: </strong>38 post-stroke patients completed the 6-month-study, 20 in the Pycnogenol<sup>®</sup> group and 18 in the control group. No side effects were observed with the supplement. The tolerability was very good. The patients included into the two groups were comparable for age, sex and clinical distribution. There were 2 dropouts in the control group, due to non-medical problems. Main COFU parameters (assessed by a cognitive questionnaire) were significantly improved (all single items) with the supplement compared to controls (P<0.05). Additional observations indicate that Pycnogenol<sup>®</sup> patients experienced significantly less mini-accidents (including falls) than controls (P<0.05). The incidences of (minor) psychotic episodes or conflicts and distress and other problems including rare occurrence of minor hallucinations, were lower with the supplementation than in controls (P<0.05). Single observations concerning daily tasks indicated a better effect of Pycnogenol<sup>®</sup> compared to controls (P<0.05). Plasma free radicals also decreased significantly with the supplement in comparison to controls (P<0.05). Globally, supplemented subjects had a better recovery than controls.</p><p><strong>Conclusions: </strong>In post-stroke subjects, Pycnogenol<sup>®</sup> supplementation resulted in better recovery outcome and faster COFU 'normalization' after the stroke in comparison with SM; it can be considered a safe, manageable post-stroke, adjuvant management possibly reducing local brain edema. Nevertheless, more patients and a longer period of evaluation are needed to confirm these results.</p>","PeriodicalId":16504,"journal":{"name":"Journal of neurosurgical sciences","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pycnogenol® improves cognitive function in post-stroke patients: a 6 month-study.\",\"authors\":\"Gianni Belcaro, Mark Dugall, Morio Hosoi, Beatrice Feragalli, Roberto Cotellese, Aristide Saggino, Maria Rosaria Cesarone, Edmondo Ippolito, Umberto Cornelli, Andrea Ledda, David B Cox\",\"doi\":\"10.23736/S0390-5616.22.05855-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This pilot study in post-stroke patients evaluated the effects of supplementation with Pycnogenol<sup>®</sup> on alterations in cognitive functions (COFU) over a period of 6 months, starting 4 weeks after the stroke.</p><p><strong>Methods: </strong>The effects of supplementation - possibly acting on residual brain edema, on global cognitive function, attention and on mental performance - were studied. A control group used standard management (SM) and the other group added Pycnogenol<sup>®</sup>, 150 mg daily to SM.</p><p><strong>Results: </strong>38 post-stroke patients completed the 6-month-study, 20 in the Pycnogenol<sup>®</sup> group and 18 in the control group. No side effects were observed with the supplement. The tolerability was very good. The patients included into the two groups were comparable for age, sex and clinical distribution. There were 2 dropouts in the control group, due to non-medical problems. Main COFU parameters (assessed by a cognitive questionnaire) were significantly improved (all single items) with the supplement compared to controls (P<0.05). Additional observations indicate that Pycnogenol<sup>®</sup> patients experienced significantly less mini-accidents (including falls) than controls (P<0.05). The incidences of (minor) psychotic episodes or conflicts and distress and other problems including rare occurrence of minor hallucinations, were lower with the supplementation than in controls (P<0.05). Single observations concerning daily tasks indicated a better effect of Pycnogenol<sup>®</sup> compared to controls (P<0.05). Plasma free radicals also decreased significantly with the supplement in comparison to controls (P<0.05). Globally, supplemented subjects had a better recovery than controls.</p><p><strong>Conclusions: </strong>In post-stroke subjects, Pycnogenol<sup>®</sup> supplementation resulted in better recovery outcome and faster COFU 'normalization' after the stroke in comparison with SM; it can be considered a safe, manageable post-stroke, adjuvant management possibly reducing local brain edema. Nevertheless, more patients and a longer period of evaluation are needed to confirm these results.</p>\",\"PeriodicalId\":16504,\"journal\":{\"name\":\"Journal of neurosurgical sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of neurosurgical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S0390-5616.22.05855-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurosurgical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0390-5616.22.05855-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:这项针对中风后患者的试验性研究评估了在中风后4周开始的6个月内补充Pycnogenol®对认知功能改变(COFU)的影响:研究了补充剂可能对残余脑水肿、整体认知功能、注意力和智力表现产生的影响。对照组使用标准管理(SM),另一组在SM中添加每日150毫克的Pycnogenol®:38名中风后患者完成了为期6个月的研究,其中Pycnogenol®组20人,对照组18人。补充剂没有副作用。耐受性非常好。两组患者的年龄、性别和临床分布相当。对照组有 2 人因非医疗问题退出。与对照组相比,服用营养补充剂后,COFU 的主要参数(通过认知问卷进行评估)明显改善(所有单项):在中风后的受试者中,与SM相比,补充Pycnogenol®能使中风后的恢复效果更好,COFU "正常化 "的速度更快;可以认为这是一种安全、可控的中风后辅助治疗方法,有可能减轻局部脑水肿。然而,要证实这些结果,还需要更多的患者和更长时间的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pycnogenol® improves cognitive function in post-stroke patients: a 6 month-study.

Background: This pilot study in post-stroke patients evaluated the effects of supplementation with Pycnogenol® on alterations in cognitive functions (COFU) over a period of 6 months, starting 4 weeks after the stroke.

Methods: The effects of supplementation - possibly acting on residual brain edema, on global cognitive function, attention and on mental performance - were studied. A control group used standard management (SM) and the other group added Pycnogenol®, 150 mg daily to SM.

Results: 38 post-stroke patients completed the 6-month-study, 20 in the Pycnogenol® group and 18 in the control group. No side effects were observed with the supplement. The tolerability was very good. The patients included into the two groups were comparable for age, sex and clinical distribution. There were 2 dropouts in the control group, due to non-medical problems. Main COFU parameters (assessed by a cognitive questionnaire) were significantly improved (all single items) with the supplement compared to controls (P<0.05). Additional observations indicate that Pycnogenol® patients experienced significantly less mini-accidents (including falls) than controls (P<0.05). The incidences of (minor) psychotic episodes or conflicts and distress and other problems including rare occurrence of minor hallucinations, were lower with the supplementation than in controls (P<0.05). Single observations concerning daily tasks indicated a better effect of Pycnogenol® compared to controls (P<0.05). Plasma free radicals also decreased significantly with the supplement in comparison to controls (P<0.05). Globally, supplemented subjects had a better recovery than controls.

Conclusions: In post-stroke subjects, Pycnogenol® supplementation resulted in better recovery outcome and faster COFU 'normalization' after the stroke in comparison with SM; it can be considered a safe, manageable post-stroke, adjuvant management possibly reducing local brain edema. Nevertheless, more patients and a longer period of evaluation are needed to confirm these results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of neurosurgical sciences
Journal of neurosurgical sciences CLINICAL NEUROLOGY-SURGERY
CiteScore
3.00
自引率
5.30%
发文量
202
审稿时长
>12 weeks
期刊介绍: The Journal of Neurosurgical Sciences publishes scientific papers on neurosurgery and related subjects (electroencephalography, neurophysiology, neurochemistry, neuropathology, stereotaxy, neuroanatomy, neuroradiology, etc.). Manuscripts may be submitted in the form of ditorials, original articles, review articles, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work.
期刊最新文献
Roxadustat protects oxidative stress and tissue injury in the brain induced by ischemic stroke via the HIF-1α/NRF2 axis. Follow-up neuroimaging after non-perimesencephalic, angiogram-negative subarachnoid hemorrhage. Tuberculum sellae meningiomas: surgical outcomes in 65 patients, review of the literature and proposal for an anatomical and radiological classification. Association of baseline frailty and age with postoperative outcomes in metastatic brain tumor patients. VEGF gene polymorphisms in Iranian patients with intracranial glioblastoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1